Brokerages Set Cryoport, Inc. (NASDAQ:CYRX) PT at $11.00

Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $11.00.

Several equities research analysts recently commented on CYRX shares. Guggenheim reiterated a "buy" rating and set a $10.00 price target on shares of Cryoport in a research note on Wednesday, April 16th. Morgan Stanley lowered their target price on shares of Cryoport from $8.00 to $7.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Needham & Company LLC reissued a "buy" rating and set a $11.00 price objective on shares of Cryoport in a report on Thursday, May 8th. Roth Mkm restated a "buy" rating and set a $15.00 target price on shares of Cryoport in a research report on Tuesday, April 1st. Finally, UBS Group boosted their price objective on shares of Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st.

Cryoport Price Performance

Shares of Cryoport stock traded up $0.05 during trading hours on Tuesday, reaching $5.95. The stock had a trading volume of 216,576 shares, compared to its average volume of 541,414. The stock's 50 day moving average is $5.95 and its 200 day moving average is $6.78. The firm has a market capitalization of $298.32 million, a PE ratio of -1.76 and a beta of 1.92. Cryoport has a twelve month low of $4.58 and a twelve month high of $11.64. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48.

Cryoport (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The company had revenue of $41.04 million during the quarter, compared to the consensus estimate of $56.19 million. Equities analysts expect that Cryoport will post -0.99 earnings per share for the current fiscal year.

Insider Activity

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the sale, the chief executive officer now directly owns 765,399 shares of the company's stock, valued at approximately $4,814,359.71. This represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders sold 19,830 shares of company stock worth $118,353. 10.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cryoport

Several large investors have recently made changes to their positions in the business. Franklin Resources Inc. lifted its position in shares of Cryoport by 0.4% in the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company's stock worth $3,012,000 after purchasing an additional 1,512 shares in the last quarter. Rhumbline Advisers boosted its stake in Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock worth $492,000 after buying an additional 1,764 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its stake in Cryoport by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after buying an additional 2,120 shares in the last quarter. Sierra Summit Advisors LLC boosted its stake in Cryoport by 5.0% during the first quarter. Sierra Summit Advisors LLC now owns 45,060 shares of the company's stock worth $274,000 after buying an additional 2,150 shares in the last quarter. Finally, Nebula Research & Development LLC lifted its holdings in shares of Cryoport by 21.6% during the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company's stock valued at $97,000 after acquiring an additional 2,207 shares during the period. Institutional investors own 92.90% of the company's stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.